Benzyl 4-(2-oxo-1-(2-oxoethyl)-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)phenylcarbamate

ID: ALA1910011

Chembl Id: CHEMBL1910011

PubChem CID: 57403163

Max Phase: Preclinical

Molecular Formula: C32H26N4O5

Molecular Weight: 546.58

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=CCN1C(=O)C(NC(=O)c2ccc(NC(=O)OCc3ccccc3)cc2)N=C(c2ccccc2)c2ccccc21

Standard InChI:  InChI=1S/C32H26N4O5/c37-20-19-36-27-14-8-7-13-26(27)28(23-11-5-2-6-12-23)34-29(31(36)39)35-30(38)24-15-17-25(18-16-24)33-32(40)41-21-22-9-3-1-4-10-22/h1-18,20,29H,19,21H2,(H,33,40)(H,35,38)

Standard InChI Key:  CUQNVYMFAAYWPC-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA1910011

   benzyl N-[4-[[2-oxo-1-(2-oxoethyl)-5-phenyl-3H-1,4-benzodiazepin-3-yl]carbamoyl]phenyl]carbamate

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 546.58

Molecular Weight (Monoisotopic): 546.1903

AlogP: 4.57

#Rotatable Bonds: 8

Polar Surface Area: 117.17

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.73

CX Basic pKa: 0.46

CX LogP: 4.65

CX LogD: 4.65

Aromatic Rings: 4

Heavy Atoms: 41

QED Weighted: 0.31

Np Likeness Score: -0.42

References

1. Qiao Z, Wang W, Wang L, Wen D, Zhao Y, Wang Q, Meng Q, Chen G, Wu Y, Zhou H..  (2011)  Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors.,  21  (21): [PMID:21930380] [10.1016/j.bmcl.2011.08.101]

2. Wei J, Wang H, Zheng Q, Zhang J, Chen Z, Wang J, Ouyang L, Wang Y..  (2022)  Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers.,  241  [PMID:35939992] [10.1016/j.ejmech.2022.114650]

Source

Source(1):

• Scientific Literature